Description

The purpose of the session is to discuss the dramatic diversification of practice standards that radiation oncology has undergone over the last decade. Many of the changes were initiated by improvements in the science and still others were driven by new capabilities and technologies. For example, standard treatments for localized breast and prostate cancer can encompass SBRT, intraoperative single, LDR and HDR brachytherapy, external beam radiation with IMRT and proton therapy. This session will address, from the perspective of payors, how they determine coverage decisions and when and how the corresponding science is evaluated.

Learning Objectives:

1. Review and reflect on the breadth of treatment options for patients with standard diseases.
2. Define the processes behind payor approval of new methodologies and technologies.
3. Diagram and describe the basic processes behind the Medicare New Medical Services and New Technologies payment policy.

Subspecialties

• Radiation Oncology

Moderator(s):

• Arthur Hung, MD

Speaker(s):

• Naomi Aronson, Ph.D
• Carl Bogardus, MD, FACR
• Paul Rudolf, JD, MD

Disclosures

• Naomi Aronson, Ph.D : <p>Naomi Aronson: None</p>
• Carl Bogardus, MD, FACR : <p>Carl Bogardus: Officer, Director-Bogardus Medical Systems Inc. [BMSi]</p>
• Arthur Hung, MD : <p>Arthur Hung: None</p>
• Paul Rudolf, JD, MD : <p>Paul Rudolf: Consultant-Genentech , Inc.|Novartis Oncology|Takeda</p>